ExeGi Pharma Probiotics to be Studied in Multiple Sclerosis Patients

ExeGi Pharma Probiotics to be Studied in Multiple Sclerosis Patients

Publication date: Sep 10, 2019

ROCKVILLE, Md. , Sept. 9, 2019 /PRNewswire/ –^A ExeGi Pharma has announced that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be examining the effects of their high potency probiotic, Visbiome, in patients with multiple sclerosis (MS).

The study will explore the effects of probiotics on the gut microbiota and immune systems of people living with MS. A previous study, published in Annals of Neurology in 2018, showed that administration of the same probiotic resulted in changes in the composition of gut microbiota in MS patients, along with an increase in anti-inflammatory biomarkers.

Rebecca Farber, MD, an assistant professor of neurology at Columbia University Vagelos College of Physicians and Surgeons, and one of the lead researchers on the study, says, “The gut microbiome plays an important role in modulating the immune system, which is dysregulated in individuals with MS. This study will enhance our understanding about whether probiotics may be able to advantageously reshape the immune system and prevent degeneration of the nervous system. “

Concepts Keywords
Biomarkers Microbiota immune systems
Biotechnology Anti inflammatory biomarkers
Biotherapeutic Gut flora
CEO Biotechnology
Drug Therapy Dysbiosis
Freeze Dried Irritable bowel syndrome
Gut Microbiota Probiotic
Hepatic Encephalopathy Gastrointestinal tract disorders
Immune System RTT
Irritable Bowel Syndrome MS
Lactic Acid Bacteria Drug therapy
Microbiome Medical specialties
Multiple Sclerosis Medicine
Nervous System Clinical medicine
Neurology Bacteriology
Physician Digestive system
Pittsburgh Abdominal pain
Probiotic Probiotics multiple sclerosis
Probiotics Biotechnology
ROCKVILLE
Scientific Community
Ulcerative Colitis

Semantics

Type Source Name
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis
disease MESH community
pathway BSID Immune System
drug DRUGBANK Lactic Acid
disease MESH dysbiosis
disease MESH ulcerative colitis
disease DOID ulcerative colitis
disease MESH irritable bowel syndrome
disease DOID irritable bowel syndrome
disease MESH hepatic encephalopathy
disease DOID hepatic encephalopathy
disease MESH pouchitis
drug DRUGBANK Isoxaflutole
disease MESH development

Leave a Comment

Your email address will not be published. Required fields are marked *